Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa

Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis

Estimates of preference-weighted health outcomes or health state utilities are needed to assess improvements in health in terms of quality-adjusted life-years. Gains in quality-adjusted life-years are used to assess the cost-effectiveness of prophylactic use of clotting factor compared with on-demand treatment among people with hemophilia, a congenital bleeding disorder. Published estimates of health utilities for people with hemophilia vary, contributing to uncertainty in the estimates of cost-effectiveness of prophylaxis. Challenges in estimating utility weights for the purpose of evaluating hemophilia treatment include selection bias in observational data, difficulty in adjusting for predictors of health-related quality of life and lack of preference-based data comparing adults with lifetime or primary prophylaxis versus no prophylaxis living within the same country and healthcare system.

New developments in the treatment of pediatric hemophilia and bleeding disorders

PURPOSE OF REVIEW

Disorders of hemostasis such as hemophilia, von Willebrand disease (VWD), and other clotting protein deficiencies lead to significant morbidity in the pediatric population. Because of the limitations of current treatment options, novel therapies are being developed, many of which are reviewed here.

RECENT FINDINGS

Several new observations about the nature of clotting protein physiology have been made recently, creating novel perspectives on the treatment options. This review will mostly focus on the current therapy as well as new progress in hemophilia care (particularly strategies to prolong half-life of clotting factor replacements, the management of inhibitors, gene therapy, and novel therapeutic approaches), and briefly mention some progress in VWD and fibrinogen deficiency therapies.

SUMMARY

New therapeutic developments have the potential to dramatically decrease morbidity and improve the quality of life of children with bleeding disorders.

Differing approaches to diagnosis and treatment of musculoskeletal complications of haemophilia in resource-rich and resource-limited settings

Management of the musculoskeletal complications of haemophilia should be consistent in both RRS (resource-rich settings) and RLS (resource-limited settings). Due to the lack of available resources in RLS, physicians face challenges that may limit their options for procedures. This article aimed to define the role of different techniques for the management of the musculoskeletal complications of haemophilia in RRS and RLS. A review of recent literature on the topic has been performed. In RLS, ultrasonography can be used as a diagnostic tool instead of MRI; chemical synovectomy can be the first alternative instead of radiosynovectomy and arthroscopic synovectomy; percutaneous treatment of pseudotumours can be performed instead of open surgical removal; finally, autologous cancellous bone can be used to fill cysts and pseudotumours instead of cancellous bone obtained from the Bone Bank. All diagnostic tools and treatments recommended for RLS have been proven to be efficacious; however, the ideal diagnosis and treatment for the musculoskeletal complications of haemophilia in RRS include MRI, radiosynovectomy, arthroscopic knee and ankle debridement in the early stages of arthropathy, total knee arthroplasty and total ankle arthroplasty or ankle fusion (in advanced stages of arthropathy), and surgical removal of pseudotumours. Treatments considered ideal in RRS should be the first therapeutic option if available. However, secondary treatment options that are less costly and therefore more readily available in RLS are perfectly valid and efficacious.

Reversal of antithrombotic agents

Anticoagulants are the mainstay of therapy for thromboembolic diseases. In addition to the more traditional agents, new oral anticoagulants, including dabigatran etexilate, rivaroxaban, and apixaban, have been shown to be effective across several indications. Bleeding is a serious complication associated with any anticoagulant, but many of the traditional parenteral and new oral agents do not currently have specific antidotes. This review describes available and future options for the reversal of the effects of anticoagulants, in particular the new oral agents and discusses current management strategies for bleeding events in clinical practice.